For the past few years, our annual World Preview report has included analysis of the potential scale of the 2025-2030 pharma patent cliff. It’s one of the features that garners the most questions from readers, particularly around how a potential loss of $300bn can sit alongside forecast growth of over 7% in the same time frame.
It’s a good question and one that our experts from Evaluate, Norstella, and Scrip have set their sights on. In our upcoming loss of exclusivity webinar, they will dig deeper into the data and look at the portfolio tactics that will be needed to address the growth gap. As one of our panelists noted in a recent planning session, “not all loss of exclusivity is created equal” so they’ll be considering how different companies are impacted, what the options are for the most-affected players, and what lessons can be learned from the LoEs of the past.
Worldwide Sales at Risk from Patent Expiry
(Source, Evaluate Pharma)
It’s going to be a fantastic discussion and I strongly recommend that you register to attend. It’ll take place on Wednesday, 29th October at 3pm GMT/11am ET and we’d love to see you there.
Register now for “Cliffhanger: Portfolio Tactics to Scale the $300bn Patent Cliff”
